Li G - Search Results

1

Molecular Dynamics Simulation on the Conformational Change of a pH-Switchable Lipid.

Zhang H, Zhuang X, Wang Y, Zhao Z, Yan L, Li G, Li J, Yan H. Zhang H, et al. Among authors: li j, li g. Langmuir. 2024 Dec 23. doi: 10.1021/acs.langmuir.4c03704. Online ahead of print. Langmuir. 2024. PMID: 39714441

2

Molecular Dynamics Study of Silica Nanoparticles and CO₂-Switchable Surfactants at an Oil-Water Interface.

Meng T, Zhao Z, Li G, Li J, Yan H. Meng T, et al. Among authors: li j, li g. Langmuir. 2023 Aug 15;39(32):11283-11293. doi: 10.1021/acs.langmuir.3c00949. Epub 2023 Jul 31. Langmuir. 2023. PMID: 37524083

3

Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPα Checkpoint Blockade for Efficient Treatment of Colon Cancer.

Chang R, Chu X, Zhang J, Fu R, Feng C, Jia D, Wang R, Yan H, Li G, Li J. Chang R, et al. Among authors: li j, li g. Molecules. 2023 Mar 31;28(7):3147. doi: 10.3390/molecules28073147. Molecules. 2023. PMID: 37049910 Free PMC article.

4

Codelivery of TRAIL and Mitomycin C via Liposomes Shows Improved Antitumor Effect on TRAIL-Resistant Tumors.

Chang R, Fu R, Huang Y, Zhang J, Feng C, Wang R, Yan H, Li G, Chu X, Yuan F, Jia D, Li J. Chang R, et al. Among authors: li j, li g. Mol Pharm. 2023 Jun 5;20(6):2864-2875. doi: 10.1021/acs.molpharmaceut.2c01013. Epub 2023 May 3. Mol Pharm. 2023. PMID: 37134184

5

Improving Targeted Delivery and Antitumor Efficacy of TRAIL through Fusion with a B7H3-Antagonistic Affibody.

Lu X, Zhan X, Xia G, Wang F, Lv M, Liu R, Liu Y, Zi C, Li G, Wang R, Li J, Yuan F, Jia D. Lu X, et al. Among authors: li j, li g. Mol Pharm. 2025 Jan 6;22(1):284-294. doi: 10.1021/acs.molpharmaceut.4c00891. Epub 2024 Dec 2. Mol Pharm. 2025. PMID: 39620978

6

Synthesis of 3,4-dihydroquinolin-2(1H)-one derivatives with anticonvulsant activity and their binding to the GABA_A receptor.

Wang S, Liu H, Lei K, Li G, Li J, Wei Y, Wang X, Liu R. Wang S, et al. Among authors: li j, li g. Bioorg Chem. 2020 Oct;103:104182. doi: 10.1016/j.bioorg.2020.104182. Epub 2020 Aug 27. Bioorg Chem. 2020. PMID: 32890992

7

Coupling EGFR-Antagonistic Affibody Enhanced Therapeutic Effects of Cisplatin Liposomes in EGFR-expressing Tumor Models.

Jia D, Wang F, Yang Y, Hu P, Song H, Lu Y, Wang R, Li G, Liu R, Li J, Yuan F. Jia D, et al. Among authors: li j, li g. J Pharm Sci. 2022 Feb;111(2):450-457. doi: 10.1016/j.xphs.2021.09.018. Epub 2021 Sep 20. J Pharm Sci. 2022. PMID: 34547305

8

Coumarin and 3,4-dihydroquinolinone derivatives: Synthesis, antidepressant activity, and molecular docking studies.

Wang SB, Liu H, Li GY, Li J, Li XJ, Lei K, Wei LC, Quan ZS, Wang XK, Liu RM. Wang SB, et al. Pharmacol Rep. 2019 Dec;71(6):1244-1252. doi: 10.1016/j.pharep.2019.07.011. Epub 2019 Jul 31. Pharmacol Rep. 2019. PMID: 31670061

9

Synthesis of 1,3,4-oxadiazole derivatives with anticonvulsant activity and their binding to the GABA_A receptor.

Wang S, Liu H, Wang X, Lei K, Li G, Li J, Liu R, Quan Z. Wang S, et al. Among authors: li j, li g. Eur J Med Chem. 2020 Nov 15;206:112672. doi: 10.1016/j.ejmech.2020.112672. Epub 2020 Aug 6. Eur J Med Chem. 2020. PMID: 32798790

10

Fusion of an EGFR-antagonistic affibody enhances the anti-tumor effect of TRAIL to EGFR positive tumors.

Jia D, Wang F, Lu Y, Hu P, Wang R, Li G, Liu R, Li J, Liu H, Fan Q, Yuan F. Jia D, et al. Among authors: li j, li g. Int J Pharm. 2022 May 25;620:121746. doi: 10.1016/j.ijpharm.2022.121746. Epub 2022 Apr 12. Int J Pharm. 2022. PMID: 35427745

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49,669 results

Search Page

Filters